Eculizumab Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[241+ Pages Report] According to Facts & Factors, the global Eculizumab market size was estimated at USD 3.5 billion in 2025 and is expected to reach USD 6.8 billion by the end of 2034. The Eculizumab industry is anticipated to grow by a CAGR of 7.6% between 2026 and 2034. The Eculizumab Market is driven by increasing diagnosis rates of rare complement-mediated diseases and expanding approved indications for the drug.

Market Overview

The Eculizumab market covers the global sales and distribution of eculizumab, a humanized monoclonal antibody that specifically binds to complement protein C5, preventing its cleavage and thereby inhibiting the formation of the terminal complement complex responsible for cell lysis and inflammation. Marketed primarily as Soliris by AstraZeneca, eculizumab is the first-in-class C5 inhibitor approved for treating life-threatening rare diseases caused by uncontrolled complement activation. It is used to manage paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. The market includes branded products, emerging biosimilars, associated infusion services, and patient support programs, serving as a cornerstone therapy that dramatically improves survival, reduces transfusion needs, and enhances quality of life for patients with these ultra-rare conditions.

Key Insights

• As per the analysis shared by our research analyst, the Eculizumab market is estimated to grow annually at a CAGR of around 7.6% over the forecast period (2026-2034).
• In terms of revenue, the Eculizumab market size was valued at around USD 3.5 billion in 2025 and is projected to reach USD 6.8 billion by 2034.
• The Eculizumab Market is driven by rising diagnoses of rare complement-mediated diseases and expanding indications.
• Based on the Type, the Soliris segment dominated the market in 2025 with a share of 82% due to its established efficacy, physician familiarity, and strong patent protection in major markets.
• Based on the Application, the Paroxysmal Nocturnal Hemoglobinuria segment dominated the market in 2025 with a share of 48%, owing to its status as the first approved indication and high unmet need for lifelong treatment.
• Based on the End-User, the Hospitals segment dominated the market in 2025 with a share of 65% because of the requirement for supervised intravenous infusion and specialized monitoring of rare disease patients.
• North America dominated the global Eculizumab market in 2025 with a share of 42%, attributed to early regulatory approvals, high diagnosis rates, favorable reimbursement for orphan drugs, and the strong presence of specialized treatment centers.

Growth Drivers

• Increasing Diagnosis of Rare Diseases

Improved genetic testing, disease awareness campaigns, and specialized registries have led to higher diagnosis rates of PNH, aHUS, and other complement disorders, directly increasing the number of patients eligible for lifelong eculizumab therapy.

Expansion of approved indications to myasthenia gravis and neuromyelitis optica spectrum disorder has significantly broadened the patient pool and driven new prescription growth.

Restraints

• Extremely High Treatment Cost

Eculizumab is one of the most expensive drugs in the world, with annual costs exceeding hundreds of thousands of dollars per patient, creating substantial barriers to access even in high-income countries with limited reimbursement or budget constraints.

Biosimilar entry is slower than expected due to complex manufacturing and regulatory hurdles, delaying price erosion and keeping the overall market value concentrated in the branded product.

Opportunities

• Biosimilar Competition and Emerging Markets

Approval and launch of cost-effective biosimilars in Europe, Asia, and other regions are expected to improve affordability and expand patient access in previously underserved markets.

Development of subcutaneous formulations and combination therapies with newer complement inhibitors could enhance patient convenience and open additional growth avenues.

Challenges

• Safety Monitoring and Infection Risk

Eculizumab increases susceptibility to meningococcal infections, requiring mandatory vaccination and ongoing patient monitoring, which adds complexity and cost to treatment protocols.

Patent expirations and legal battles over biosimilar approvals create uncertainty for both originator and follow-on manufacturers, affecting investment and market planning.

Report Scope

Market Segmentation

The Eculizumab market is segmented by type, application, end-user, and region.

Based on Type Segment, the Eculizumab market is divided into Soliris, biosimilar eculizumab, eculizumab biosimilar, and others. The most dominant segment is Soliris, followed by Biosimilar Eculizumab. Soliris dominates due to its first-mover advantage, extensive clinical data, physician preference, and strong patent protection in key markets, which sustains premium pricing and high revenue contribution while biosimilars gradually erode share in price-sensitive regions.

Based on Application Segment, the Eculizumab market is divided into paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, and others. The most dominant segment is Paroxysmal Nocturnal Hemoglobinuria, followed by Atypical Hemolytic Uremic Syndrome. Paroxysmal Nocturnal Hemoglobinuria leads because it was the first approved indication, requires lifelong therapy, and has a very high unmet need, generating consistent high-value prescriptions that anchor the market and support expansion into newer indications.

Based on End-User Segment, the Eculizumab market is divided into hospitals, specialty clinics, home healthcare, and others. The most dominant segment is Hospitals, followed by Specialty Clinics. Hospitals dominate because eculizumab requires initial supervised intravenous administration, specialized monitoring for infusion reactions, and multidisciplinary care teams typical of rare disease management, creating the greatest institutional demand and serving as the primary channel for treatment initiation.

Recent Developments

• In February 2025, AstraZeneca received expanded approval for Soliris in additional pediatric indications for atypical hemolytic uremic syndrome in key Asian markets.
• In November 2024, Sandoz launched the first eculizumab biosimilar in Europe, offering significant cost savings for healthcare systems.
• In April 2025, a major Indian biosimilar manufacturer announced Phase 3 results for its eculizumab biosimilar targeting emerging markets.
• In January 2025, Alexion introduced a new patient support program with home infusion options for eligible myasthenia gravis patients.
• In June 2025, regulatory authorities in several Latin American countries approved the first local biosimilar version of eculizumab.

Regional Analysis

• North America to dominate the global market

North America leads the Eculizumab market through early regulatory approvals, high diagnosis rates for rare diseases, robust reimbursement mechanisms for orphan drugs, and a strong presence of specialized treatment centers. High healthcare expenditure and patient advocacy groups further support access to this high-cost therapy. The United States dominates within North America owing to its large patient population eligible for treatment, favorable orphan drug incentives, and leadership in clinical research that continues to expand the drug’s approved indications and real-world evidence base.

Europe represents a substantial share of the Eculizumab market, supported by centralized EMA approvals, national reimbursement schemes for rare diseases, and increasing adoption of biosimilars to manage budget impact. Strong collaboration between reference centers and payers ensures consistent access. Germany stands out through its advanced rare disease networks, high per-capita spending on specialty medicines, and proactive approach to biosimilar uptake in hospital formularies.

Asia Pacific is experiencing the fastest growth in the Eculizumab market, driven by improving diagnosis infrastructure, rising healthcare spending, and gradual regulatory acceptance of biosimilars in key countries. Growing awareness among physicians and patients supports higher treatment uptake. China dominates the region with its large population, expanding rare disease registries, and government efforts to include high-cost biologics in national reimbursement lists where possible.

Latin America shows a gradual uptake in the Eculizumab market as healthcare systems strengthen rare disease programs and local biosimilar approvals improve affordability. Brazil and Mexico lead with relatively developed private insurance and hospital networks that facilitate access to specialty therapies.

The Middle East & Africa region demonstrates emerging demand for Eculizumab,  supported by investments in specialized hospitals and increasing medical tourism for rare disease treatment. The United Arab Emirates and Saudi Arabia lead with modern healthcare facilities and government initiatives to provide advanced therapies for rare conditions.

Competitive Analysis

The global Eculizumab market is dominated by players:

• AstraZeneca 
• Amgen Inc.
• Samsung Bioepis
• Teva Pharmaceuticals

The global Eculizumab market is segmented as follows:

By Type

• Soliris
• Biosimilar Eculizumab
• Eculizumab Biosimilar
• Others

By Application

• Paroxysmal Nocturnal Hemoglobinuria
• Atypical Hemolytic Uremic Syndrome
• Generalized Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder
• Others

By End-User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America